Cardiotoxicity of Chemotherapy: A Multi-OMIC Perspective

Journal of Xenobiotics, Journal Year: 2025, Volume and Issue: 15(1), P. 9 - 9

Published: Jan. 8, 2025

Chemotherapy-induced cardiotoxicity is a critical issue in cardio-oncology, as cancer treatments often lead to severe cardiovascular complications. Approximately 10% of patients succumb problems, with lung frequently experiencing arrhythmias, cardiac failure, tamponade, and metastasis. The cardiotoxic effects anti-cancer manifest at both cellular tissue levels, causing deformation cardiomyocytes, leading contractility issues fibrosis. Repeated irradiation chemotherapy increase the risk valvular, pericardial, or myocardial diseases. Multi-OMICs analyses reveal that targeting specific pathways well protein modifications, such ubiquitination phosphorylation, could offer potential therapeutic alternatives current treatments, including Angiotensin converting enzymes (ACE) inhibitors beta-blockers mitigate symptoms but do not prevent cardiomyocyte death, highlighting need for more effective therapies manage defects survivors. This review explores xenobiotic nature agents their impact on health, aiming identify novel biomarkers targets cardiotoxicity.

Language: Английский

Urolithin A attenuates Doxorubicin-induced cardiotoxicity by enhancing PINK1-regulated mitophagy via Ambra1

Chemico-Biological Interactions, Journal Year: 2024, Volume and Issue: 406, P. 111363 - 111363

Published: Dec. 24, 2024

Language: Английский